Logo image of TNG.PA

TRANSGENE SA (TNG.PA) Stock Price, Quote, News and Overview

EPA:TNG - Euronext Paris - Matif - FR0005175080 - Common Stock - Currency: EUR

0.59  0 (-0.34%)

TNG.PA Quote, Performance and Key Statistics

TRANSGENE SA

EPA:TNG (5/13/2025, 7:00:00 PM)

0.59

0 (-0.34%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High1.35
52 Week Low0.55
Market Cap78.05M
Shares132.29M
Float35.02M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PE10.62
Earnings (Next)09-16 2025-09-16
IPO03-25 1998-03-25


TNG.PA short term performance overview.The bars show the price performance of TNG.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -5 -10 -15 -20 -25

TNG.PA long term performance overview.The bars show the price performance of TNG.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of TNG.PA is 0.59 EUR. In the past month the price decreased by -7.48%. In the past year, price decreased by -55.2%.

TRANSGENE SA / TNG Daily stock chart

TNG.PA Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
4AB.DE ABBVIE INC 18.16 297.19B
AMG.DE AMGEN INC 13.18 132.40B
1GILD.MI GILEAD SCIENCES INC 13.27 115.15B
GIS.DE GILEAD SCIENCES INC 13.04 113.13B
VX1.DE VERTEX PHARMACEUTICALS INC N/A 100.62B
1REGN.MI REGENERON PHARMACEUTICALS 11.72 52.64B
ARGX.BR ARGENX SE 101.39 29.84B
22UA.DE BIONTECH SE-ADR N/A 20.77B
IDP.DE BIOGEN INC 7.79 16.26B
1MRNA.MI MODERNA INC N/A 8.90B
0QF.DE MODERNA INC N/A 8.86B
BIO.DE BIOTEST AG 65.54 1.69B

About TNG.PA

Company Profile

TNG logo image Transgene SA is a biotechnology company that focuses on designing and developing targeted immunotherapies for the treatment of cancer. The company is headquartered in Illkirch-Graffenstaden, Grand Est and currently employs 158 full-time employees. The firm designs and develops immunotherapy products to treat cancer and infectious diseases. These products use viral vectors to directly or indirectly destroy diseased cells. The firm has approximately three products in clinical development: two immunotherapy products for cancer treatment and an anti-infective immunotherapy product for chronic hepatitis B. The firm also has various other programs based on its viral vector technology in research or in pre-clinical or clinical development. The firm's activities are focused on human health and, in particular, the research and development of immunotherapy products, including therapeutic vaccines and oncolytic viruses in the field of cancer and infectious diseases. The firm's principal products include TG4010 (MVA-MUC1-IL2), Pexa-Vec (VV-TK-GM-CSF), TG6002 (VV-TK-RR-FCU1), TG1050 (Ad5-HBV) and TG4001 (MVA-HPV-IL2).

Company Info

TRANSGENE SA

400 Boulevard Gonthier d'Andernach, Parc d'Innovation - CS80166, Cedex

Illkirch-Graffenstaden GRAND EST FR

Employees: 144

TNG Company Website

TNG Investor Relations

Phone: 33388279100

TRANSGENE SA / TNG.PA FAQ

What is the stock price of TRANSGENE SA today?

The current stock price of TNG.PA is 0.59 EUR. The price decreased by -0.34% in the last trading session.


What is the ticker symbol for TRANSGENE SA stock?

The exchange symbol of TRANSGENE SA is TNG and it is listed on the Euronext Paris - Matif exchange.


On which exchange is TNG.PA stock listed?

TNG.PA stock is listed on the Euronext Paris - Matif exchange.


What is the price forecast or stock price prediction for TRANSGENE SA stock?

7 analysts have analysed TNG.PA and the average price target is 1.73 EUR. This implies a price increase of 193.9% is expected in the next year compared to the current price of 0.59. Check the TRANSGENE SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is TRANSGENE SA worth?

TRANSGENE SA (TNG.PA) has a market capitalization of 78.05M EUR. This makes TNG.PA a Micro Cap stock.


How many employees does TRANSGENE SA have?

TRANSGENE SA (TNG.PA) currently has 144 employees.


What are the support and resistance levels for TRANSGENE SA (TNG.PA) stock?

TRANSGENE SA (TNG.PA) has a resistance level at 0.61. Check the full technical report for a detailed analysis of TNG.PA support and resistance levels.


Is TRANSGENE SA (TNG.PA) expected to grow?

The Revenue of TRANSGENE SA (TNG.PA) is expected to decline by -44.69% in the next year. Check the estimates tab for more information on the TNG.PA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy TRANSGENE SA (TNG.PA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does TRANSGENE SA (TNG.PA) stock pay dividends?

TNG.PA does not pay a dividend.


When does TRANSGENE SA (TNG.PA) report earnings?

TRANSGENE SA (TNG.PA) will report earnings on 2025-09-16.


What is the Price/Earnings (PE) ratio of TRANSGENE SA (TNG.PA)?

TRANSGENE SA (TNG.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.22).


TNG.PA Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

TNG.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to TNG.PA. Both the profitability and financial health of TNG.PA have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

TNG.PA Financial Highlights

Over the last trailing twelve months TNG.PA reported a non-GAAP Earnings per Share(EPS) of -0.22. The EPS increased by 32.67% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -43.99%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%N/A
Sales Q2Q%N/A
EPS 1Y (TTM)32.67%
Revenue 1Y (TTM)-23.68%

TNG.PA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to TNG.PA. The Buy consensus is the average rating of analysts ratings from 7 analysts.

For the next year, analysts expect an EPS growth of 28% and a revenue growth -44.69% for TNG.PA


Ownership
Inst Owners0.93%
Ins Owners0.7%
Short Float %N/A
Short RatioN/A
Analysts
Analysts82.86
Price Target1.73 (193.22%)
EPS Next Y28%
Revenue Next Year-44.69%